Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Finance of America Q1 2026 Earnings Call - Reverse Mortgage Volumes Surge on Proprietary Product Momentum
Finance of America delivered a standout first quarter for 2026, with net income jumping 112% year-over-year to $35 million and adjusted EPS reaching $1.10. The company funded $596 million in reverse m...
- Net income surged 112% year-over-year to $35 million, with adjusted EPS of $1.10, significantly outpacing prior year results and beating management's initial guidance.
- Funded volumes reached $596 million, up 6% year-over-year, supported by a 20% increase in submissions to $918 million, signaling strong pipeline momentum.
- Proprietary reverse mortgage products, specifically HomeSafe Second, saw a 32% year-over-year increase, highlighting a strategic shift toward higher-margin, bespoke lending solutions.
- +7 more takeaways
AtriCure (ATRC) Q1 2026 Earnings Call - BoxX-NoAF Enrollment Surges Ahead of Schedule, Driving 14% Revenue Growth
AtriCure delivered a robust Q1 2026, with worldwide revenue reaching $141.2 million, a 14.3% year-over-year increase, and adjusted EBITDA nearly doubling to $17.1 million. The results were primarily f...
- Revenue acceleration: Worldwide revenue grew 14.3% year-over-year to $141.2 million, with U.S. revenue up 14.9% to $116.2 million, driven by expanding adoption of new devices.
- Profitability expansion: Adjusted EBITDA nearly doubled to $17.1 million, up 95% from Q1 2025, while gross margin improved by 246 basis points to 77.4% due to favorable product and geographic mix.
- BoxX-NoAF trial ahead of schedule: The randomized controlled trial for postoperative atrial fibrillation has enrolled approximately 300 patients and is tracking nearly a year ahead of plan, with full enrollment expected by year-end 2026.
- +7 more takeaways
MNTN Q1 2026 Earnings Call - Record Profitability and AI-Driven Growth Accelerate
MNTN delivered a standout first quarter, posting 25% year-over-year revenue growth to $73.7 million and achieving record positive net income of $8.8 million. The company’s adjusted EBITDA surged 74% t...
- Revenue reached $73.7 million, up 25% year-over-year, beating prior guidance and reflecting strong adoption of Performance TV across new customer segments.
- Adjusted EBITDA jumped 74% to $16.3 million, with the adjusted EBITDA margin expanding 770 basis points to 22.2% as operating leverage kicked in.
- Gross margins improved to 81%, a 1,220 basis point year-over-year increase, driven by the divestiture of Maximum Effort, reduced hosting costs, and revenue mix shifts.
- +7 more takeaways
Veracyte Q1 2026 Earnings Call - Profitability Surges as Core Franchises Accelerate and New Launches Loom
Veracyte delivered a strong start to 2026, with Q1 revenue rising 21% year-over-year to $139.1 million and adjusted EBITDA jumping 73% to $42.8 million, or 30.8% of revenue. The company raised full-ye...
- Q1 2026 total revenue reached $139.1 million, up 21% year-over-year, with testing revenue of $135.1 million, up 26% year-over-year.
- Adjusted EBITDA surged 73% year-over-year to $42.8 million, representing 30.8% of revenue, well above the long-term 25% target.
- Full-year 2026 revenue guidance was raised to $582 million–$592 million (13%–14% growth), and adjusted EBITDA guidance was increased to greater than 26%.
- +7 more takeaways
Schrödinger Q1 2026 Earnings Call - Accelerated Hosted Shift and Bunsen AI Drive Software Momentum
Schrödinger reported Q1 2026 ACV of $28.4 million, up 12% year-over-year, with software revenue reaching $35.6 million as the company accelerates its transition to hosted licensing. Hosted revenue now...
- ACV grew 12% to $28.4 million in Q1 2026, with broad-based usage scale-ups across top 20 pharma customers.
- Hosted licensing transition is accelerating, now comprising 34% of software revenue, up from 24% in Q1 2025.
- Software revenue reached $35.6 million, while drug discovery revenue doubled to $22.9 million due to milestone recognitions.
- +7 more takeaways
Latham Group Q1 2026 Earnings Call - Margin Expansion Driven by Lean Manufacturing and Sunbelt Strategy
Latham Group delivered a solid Q1 2026 despite adverse weather, with net sales rising 5% to $117 million and adjusted EBITDA up 9% to $12 million. The company’s gross margin expanded 220 basis points ...
- Net sales rose 5% year-over-year to $117 million, with 3% organic growth and 2% from the one-month contribution of the Freedom Pools acquisition.
- Gross margin expanded 220 basis points to 32%, driven by volume leverage and lean manufacturing/value engineering initiatives.
- Adjusted EBITDA grew 9% to $12 million, with margin expanding 40 basis points to 10.4% despite higher SG&A.
- +9 more takeaways
Accel Entertainment Q1 2026 Earnings Call - Record Revenue and EBITDA Driven by Market Expansion and Operational Discipline
Accel Entertainment delivered a record-breaking first quarter of 2026, with revenue climbing 9% year-over-year to $352 million and adjusted EBITDA rising 9% to $54 million. The results underscore the ...
- Revenue reached an all-time quarterly high of $352 million, up 9% year-over-year, driven by broad-based strength across Illinois, Nebraska, Georgia, Nevada, and Louisiana.
- Adjusted EBITDA grew 9% to $54 million, reflecting disciplined execution and operating leverage as the company scales in developing markets.
- Illinois, the company’s largest market, delivered 6% revenue growth with a 9% year-over-year increase in hold per day, supported by strategic route pruning and the full rollout of TITO-enabled terminals.
- +7 more takeaways
Supernus Pharmaceuticals Q1 2026 Earnings Call - ONAPGO Rebound and ZURZUVAE Momentum Drive 39% Revenue Growth
Supernus Pharmaceuticals reported a robust first quarter of 2026, with total revenue surging 39% year-over-year to $207.7 million. The growth was fueled by a strong rebound in ONAPGO following the res...
- Total revenue rose 39% year-over-year to $207.7 million, driven by commercial product growth and a $20 million Shionogi commercial milestone.
- ONAPGO net sales reached $8.4 million in Q1 2026, reflecting a partial recovery after the resumption of new patient initiations in February 2026.
- Over 2,200 ONAPGO enrollment forms have been submitted since launch, with March prescriptions hitting 463, exceeding pre-constraint levels.
- +9 more takeaways
Rigel Pharmaceuticals Q1 2026 Earnings Call - 26% Sales Growth and R289 Pipeline Progress Offset by Lilly Deal Termination
Rigel Pharmaceuticals delivered a strong start to 2026, with Q1 net product sales jumping 26% to $54.9 million. The growth was led by a 31% surge in TAVALISSE and a matching 31% rise in REZLIDHIA, par...
- Q1 2026 net product sales reached $54.9 million, a 26% year-over-year increase, driven by strong commercial execution across the product portfolio.
- TAVALISSE sales surged 31% to $37.3 million, benefiting from favorable gross-to-net dynamics and sustained demand despite seasonal reimbursement headwinds.
- REZLIDHIA sales grew 31% to $8.0 million, with management highlighting a strategic push to improve community adoption through post-venetoclax efficacy data.
- +7 more takeaways
Teradata Q1 2026 Earnings Call - AI-Driven Recurring Revenue Outperformance
Teradata delivered a strong start to 2026, with total revenue growing 6% year-over-year and recurring revenue jumping 12%, beating the top end of guidance. Non-GAAP EPS came in at $0.88, up over 30% y...
- Total revenue grew 6% year-over-year to $444 million, beating the high end of guidance by 3 points, driven by a 12% jump in recurring revenue.
- Non-GAAP EPS came in at $0.88, exceeding the top end of guidance by $0.09, reflecting strong operating leverage and recurring revenue growth.
- Recurring revenue hit $400 million, up 12% year-over-year, with upfront on-premise term licenses contributing 5 points of growth.
- +12 more takeaways